- Home
- PROK vs LRMR Comparison
PROK vs LRMR Comparison
Compare PROK & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | LRMR |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.2M | 280.0M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PROK | LRMR |
|---|---|---|
| Price | $2.09 | $2.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $7.40 | ★ $16.50 |
| AVG Volume (30 Days) | 844.7K | ★ 1.1M |
| Earning Date | 02-21-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $76,000.00 | N/A |
| Revenue This Year | $1,010.19 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $1.61 |
| 52 Week High | $7.13 | $5.37 |
Technical Indicators
Market Signals| Indicator | PROK | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 38.53 |
| Support Level | $1.87 | $2.89 |
| Resistance Level | $2.23 | $3.12 |
| Average True Range (ATR) | 0.16 | 0.20 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 86.47 | 13.89 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.